Tislelizumab Combined With Chemotherapy and Relayed Radiotherapy in First-line Treatment of ES-SCLC

Exclusion Criteria

• •1. Active leptomeningeal disease or uncontrolled, untreated brain metastasis;
• •2. Prior therapy with an antibody or drug against immune checkpoint pathways, including but not limited to, anti program death receptor-1 (anti-PD-1), anti-PD-L1, or anti cytotoxic T lymphocyte associated antigen 4 (anti CTLA-4) antibody;
• •3. Was administered a live vaccine ≤ 4 weeks before treatment;
• •4. Active autoimmune diseases or history of autoimmune diseases that may relapse;
• •5. Any condition that required systemic treatment with either corticosteroids or other immunosuppressive medication ≤ 14 days before treatment;
• •6. With a history of interstitial lung disease, non-infectious pneumonitis, or uncontrolled systemic diseases;
• •7. Severe chronic or active infections requiring systemic antibacterial, antifungal or antiviral therapy within 2 weeks prior to treatment, including but not limited to tuberculosis infection;
• •8. Received therapeutic oral or intravenous (IV) antibiotics within 2 weeks prior to starting treatment;